Glaxo, Plaintiffs Battle over Certification of Common Paxil Issues

PHILADELPHIA - Plaintiffs have bitten back at a brief opposing their motion to certify a class of plaintiffs who suffered injury as a result of ingesting Paxil and now seek resolution of several issues that are common to their claims against manufacturer GlaxoSmithKline. Blain, et al. v. GlaxoSmithKline, No. 06-1247 (E.D. Pa.).

The Nov. 6 brief filed in the U.S. District Court for the Eastern District of Pennsylvania rebuts GlaxoSmithKline's contention that class certification of the claims is inappropriate because individual issues raised by the plaintiffs who took Paxil will predominate.

GlaxoSmithKline asserted in their opposition that the plaintiffs, 'in …